Trastuzumab deruxtecan (T-DXd), which conjugates a topoisomerase I inhibitor to the trastuzumab scaffold, demonstrates high efficacy across HER2-expressing breast, gastric, and gynaecologic tumours
The four components span distinct structural classes and non-overlapping pathway layers: BPC-157 for angiogenic and growth-factor signaling, GHK-Cu for copper-mediated extracellular-matrix and collagen biology, TB-500 (Thymosin Beta-4) for actin-driven cell migration, and KPV (the C-terminal -MSH fragment) for NF-B and inflammatory-cytokine modulation
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG- GI004/SWOG-S1610): A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer
The anti-aging effects become clearly visible
[Google Scholar] 37.Shah N.J., Royer A., John S